Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer

NCT00140075 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00140075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00140075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2000
Completion date
August 31, 2006
Enrollment
606 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma